1. Market Research
  2. > Diagnostics Market Trends
  3. > Global Predictive Diagnostics Industry

Global Predictive Diagnostics Industry

  • April 2015
  • -
  • Global Industry Analysts
  • -
  • 175 pages

This report analyzes the worldwide markets for Predictive Diagnostics in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 49 companies including many key and niche players such as -

Abbott Molecular
Almac Group Ltd.
BioGenex
Covance, Inc.
Dako Denmark A/S

Table Of Contents

Global Predictive Diagnostics Industry



I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Curtain Raiser II-1
Predictive Diagnostics - A Key Segment of Genetic Testing II-1
Outlook for Predictive Diagnostics Market II-2

2. MAJOR MARKET TRENDS, DRIVERS, AND ISSUES II-3
Prospects for Predictive Genetic Diagnostics Grow Brighter II-3
Increasing Incidence and Prevalence of CDDs: A Major Growth
Driver II-3
Diagnosed Cases of Cancer on the Rise II-4
Table 1: Worldwide Incidence of Cancer in Million: 2012, 2020 and
2030 (includes corresponding Graph/Chart) II-4

Table 2: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America and the Caribbean, and Africa (includes corresponding
Graph/Chart) II-5

Table 3: New Cancer Cases in the World by Affected Site: 2012
(in Thousands) (includes corresponding Graph/Chart) II-6

Table 4: Global Cancer Incidence by Income Group: 2012 (in
Thousands) (includes corresponding Graph/Chart) II-7
Predictive Diagnostics - Crucial for Breast Cancer Management II-7
Table 5: World Breast Cancer Statistics: Top 20 Countries
with Highest Breast Cancer Rates (includes corresponding
Graph/Chart) II-8
Incidence of Neurodegenerative Diseases Increasing II-8
Alzheimer's Disease II-9
Huntington's Disease II-9
Quick Facts on the Global Prevalence of Huntington's Disease II-10
Parkinson's Disease II-11
Ballooning Global Population Offers Significant Growth
Opportunities II-11
Table 6: Top 25 Countries Worldwide in Terms of Population
(2015E) (includes corresponding Graph/Chart) II-12
Predictive Diagnostics Enable Higher Life Expectancy II-12
Table 7: Life Expectancy at Age 60 and 80 Years -
(2010-2015), (2020-2025) and (2045-2050) (includes
corresponding Graph/Chart) II-13

Table 8: Global Population Statistics for the 65+ Age Group:
2013 (includes corresponding Graph/Chart) II-14

Table 9: Global 60+ Years Population as a Percentage of Total
Population by Geographic Region (2013) (includes
corresponding Graph/Chart) II-15

Table 10: Global Aging Population (2013): Population in the
Age Groups 60-64, 65-79 and 80 above as a Percentage of Total
Population by Major Geographic Regions (includes
corresponding Graph/Chart) II-16
Pharmacogenomics Development Augurs Growth of Predictive
Diagnostics II-16
Discovery of Novel Biomarkers - Crucial to Predictive Diagnostics II-17
Next-Generation Sequencing - A Giant Leap in Genome Sequencing II-18
Breast Cancer Gene Testing Market to Expand Strongly II-18
Myriad Genetics - The Unquestioned Leader in Breast Cancer
Testing II-19
Growing Direct-to-Consumer Genetic Testing: Boon or Bane?? II-19
Genomic Research Remains Confined to Fundamental Research II-20
Unresolved Issues Hamper Widespread Implementation of Genetic
Diagnosis and Testing for Monogenetic Disease II-20
Dearth of Genetic Counselors - A Major Hurdle for the
Predictive Genetic Testing II-21
Framework for Validation, Regulation, and Ethical Issues - The
Need of the Hour II-21

3. PRODUCT OVERVIEW II-23
Introduction II-23
Underlying Principles of Predictive Diagnostics II-23
Predictive Diagnostics Vis-a-vis Conventional Testing II-23
Characteristics of an Effective Predictive Diagnostic Test II-24
Applications of Predictive Diagnostics II-24
Pre-Symptomatic II-24
Predisposition Testing II-24
Cancer Testing II-24
Carrier Identification II-24
Pharmacogenetics II-25
Pharmacogenomics II-25
Prenatal Diagnosis II-25
Steps in Genetic Testing Process II-25
Limitations II-25
Risks and Other Limitations of Genetic Testing II-26
Select Diseases Identified Using Predictive Diagnostics II-26
Cystic Fibrosis II-26
Breast and Ovarian Cancer (BRCA) II-26
Alzheimer's Disease II-26
Colorectal Cancer II-26
Hemochromatosis (HH) II-27
Huntington's Disease (HD) II-27
Costs of Select Tests II-27
Table 11: Costs of Select Genetic Tests II-27
Medical Ethics Surrounding Predictive Diagnostics II-27

4. PRODUCT INTRODUCTIONS II-28
Genomic Health Reports Positive Clinical Study Results of
Oncotype DX Test II-28
Genetic Technologies Limited Launches BREVA Genplus II-28
Myriad Genetics Reports Positive Trial Results for MyRisk
Diagnostic Test II-28
SRL Diagnostics Launches ST2 Test to Predict Heart Failure II-28
ColDx Assay by Almac Validated as Colon Cancer Biomarker II-28
LabCorp. Launches Several Cancer Assays II-28
MolecularMD Develops and Validates Assay Tests to Determine
LKB1 Expression and Mutation Status II-29
Abbott's Galectin-3 Assay Awarded CE Marking II-29
Asuragen Introduces BRAF and KRAS Mutation Testing Services II-29

5. RECENT INDUSTRY ACTIVITY II-30
MedImmune Completes Acquisition of Definiens II-30
LabCorp. to Acquire Covance II-30
Myriad to Market EndoPredict Test by Sividon Diagnostics II-30
QIAGEN Takes Over Ingenuity Systems II-30
Cenix to Partner with Debiopharm II-30
MolecularMD Corp. Obtains License for LKB1 Gene Technology II-30
Agilent Acquires Dako II-31
Celgene Takes Over Avila Therapeutics II-31
Signal Genetics Acquires ChipDX II-31
Roche and Med Fusion Form Strategic Alliance II-31
Epistem Inks Supply and Distribution Agreement with Becton
Dickinson for Tuberculosis Test II-31
Rosetta Genomics Signs Co-Marketing Agreement with Precision
Therapeutics II-31
Quintiles Establishes Oxford Cancer Biomarkers for
Personalized Medicine Care II-32
Cornell University Licenses microRNA Diagnostic IP to Prolias
Technologies II-32
Signal Genetics Introduces ResultsPXâ„¢ Analysis Tool and
Physician Web Portal for Genetic Test Results II-32

6. FOCUS ON SELECT KEY PLAYERS II-33
Abbott Molecular (US) II-33
Almac Group Ltd. (Ireland) II-33
BioGenex (US) II-33
Covance, Inc. (US) II-34
Dako Denmark A/S (Denmark) II-34
Epistem Plc. (UK) II-35
F. Hoffmann-La Roche Ltd. (Switzerland) II-35
Genomic Health, Inc. (US) II-36
MDxHEALTH, Inc. (US) II-37
Myriad Genetics, Inc. (US) II-37
Precision Therapeutics, Inc. (US) II-37
Prometheus Laboratories (US) II-38
QIAGEN N.V. (The Netherlands) II-38

7. GLOBAL MARKET PERSPECTIVE II-40
Table 12: World Recent Past, Current and Future Analysis for
Predictive Diagnostics by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, and Rest of World Markets
Independently Analyzed with Annual Revenue Figures in US$
Thousand for the Years 2014 through 2020 (includes
corresponding Graph/Chart) II-40

Table 13: World Historic Review for Predictive Diagnostics by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for the Years 2009 through
2013 (includes corresponding Graph/Chart) II-41

Table 14: World 12-Year Perspective for Predictive Diagnostics
by Geographic Region - Percentage Breakdown of Dollar Revenues
for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Markets for the Years 2009, 2015 and 2020 (includes
corresponding Graph/Chart) II-42


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Market Outlook III-1
Genetic Information Nondiscrimination Act (GINA) Boosts
Genetic Testing III-1
High Frequency of Predictive CFTR Screening in Expectant
Mothers III-1
Cancer Stats - Opportunity Indicator III-1
Table 15: New Cancer Cases in the US by Gender and Affected
Site: 2014E(includes corresponding Graph/Chart) III-2

Table 16: Incidence of Cancer for All Body Sites by Gender and
Age Group in the US (2013): New Cancer Cases for Males and
Females for the Age groups Under 45 years; 45 years and
Above; Under 65 years; 65 years and Above (includes
corresponding Graph/Chart) III-3

Table 17: The US Breast Cancer Incidence in Women by State
(2013): New Cases of Breast Cancer in Leading 15 States
(includes corresponding Graph/Chart) III-4
Product Introductions III-4
Strategic Corporate Developments III-5
Select Key Players III-7
B.Market Analytics III-13
Table 18: The US Recent Past, Current and Future Analysis for
Predictive Diagnostics Market Analyzed with Annual Revenue
Figures in US$ Thousand for the Years 2014 through 2020
(includes corresponding Graph/Chart) III-13

Table 19: The US Historic Review for Predictive Diagnostics
Market Analyzed with Annual Revenue Figures in US$ Thousand
for the Years 2009 through 2013 (includes corresponding
Graph/Chart) III-14

2. CANADA III-15
A.Market Analysis III-15
Cancer Statistics in Canada: Opportunity Indicator III-15
Table 20: New Cancer Cases in Canada by Gender and Affected
Site: 2014E (includes corresponding Graph/Chart) III-15

Table 21: New Cancer Cases in Canada by Province: 2014E
(includes corresponding Graph/Chart) III-16

Table 22: New Cancer Cases in Canada by Age Group: 2014E
(includes corresponding Graph/Chart) III-17
B.Market Analytics III-18
Table 23: Canadian Recent Past, Current and Future Analysis
for Predictive Diagnostics Market Analyzed with Annual
Revenue Figures in US$ Thousand for the Years 2014 through
2020 (includes corresponding Graph/Chart) III-18

Table 24: Canadian Historic Review for Predictive
Diagnostics Market Analyzed with Annual Revenue Figures in
US$ Thousand for the Years 2009 through 2013 (includes
corresponding Graph/Chart) III-19

3. JAPAN III-20
Market Analysis III-20
Table 25: Japanese Recent Past, Current and Future Analysis
for Predictive Diagnostics Market Analyzed with Annual
Revenue Figures in US$ Thousand for the Years 2014 through
2020 (includes corresponding Graph/Chart) III-20

Table 26: Japanese Historic Review for Predictive
Diagnostics Market Analyzed with Annual Revenue Figures in
US$ Thousand for the Years 2009 through 2013 (includes
corresponding Graph/Chart) III-21

4. EUROPE III-22
A.Market Analysis III-22
Predictive Testing to Dominate Genetic Testing and Screening
Services in Europe III-22
Table 27: European Genetic Testing Market by Type (2014 and
2018E): Percentage Breakdown of Diagnostic, Predictive, and
Relationship Testing Revenue (includes corresponding
Graph/Chart) III-22
Hassles Faced by European Genetic Testing Market III-23
Cancer Statistics in Europe III-23
Table 28: Number of New Cancer Cases in Europe: 2012-2030
(includes corresponding Graph/Chart) III-23
B.Market Analytics III-24
Table 29: European Recent Past, Current and Future Analysis
for Predictive Diagnostics by Geographic Region - France,
Germany, Italy, UK, and Rest of Europe Markets Independently
Analyzed with Annual Revenue Figures in US$ Thousand for the
Years 2014 through 2020 (includes corresponding Graph/Chart) III-24

Table 30: European Historic Review for Predictive
Diagnostics by Geographic Region - France, Germany, Italy,
UK, and Rest of Europe Markets Independently Analyzed with
Annual Revenue Figures in US$ Thousand for the Years 2009
through 2013 (includes corresponding Graph/Chart) III-25

Table 31: European 12-Year Perspective for Predictive
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Revenues for France, Germany, Italy, UK, and Rest of
Europe Markets for the Years 2009, 2015 and 2020 (includes
corresponding Graph/Chart) III-26

4a. FRANCE III-27
Market Analysis III-27
Table 32: French Recent Past, Current and Future Analysis for
Predictive Diagnostics Market Analyzed with Annual Revenue
Figures in US$ Thousand for the Years 2014 through 2020
(includes corresponding Graph/Chart) III-27

Table 33: French Historic Review for Predictive Diagnostics
Market Analyzed with Annual Revenue Figures in US$ Thousand
for the Years 2009 through 2013 (includes corresponding
Graph/Chart) III-28

4b. GERMANY III-29
A.Market Analysis III-29
German Ethics Council Releases Recommendations for Genetic
Testing III-29
Proposals Mentioned: A Snapshot III-29
Strategic Corporate Development III-30
IMGM Laboratories GmbH - A Key Player III-30
B.Market Analytics III-31
Table 34: German Recent Past, Current and Future Analysis for
Predictive Diagnostics Market Analyzed with Annual Revenue
Figures in US$ Thousand for the Years 2014 through 2020
(includes corresponding Graph/Chart) III-31

Table 35: German Historic Review for Predictive Diagnostics
Market Analyzed with Annual Revenue Figures in US$ Thousand
for the Years 2009 through 2013 (includes corresponding
Graph/Chart) III-32

4c. ITALY III-33
Market Analysis III-33
Table 36: Italian Recent Past, Current and Future Analysis for
Predictive Diagnostics Market Analyzed with Annual Revenue
Figures in US$ Thousand for the Years 2014 through 2020
(includes corresponding Graph/Chart) III-33

Table 37: Italian Historic Review for Predictive Diagnostics
Market Analyzed with Annual Revenue Figures in US$ Thousand
for the Years 2009 through 2013 (includes corresponding
Graph/Chart) III-34

4d. THE UNITED KINGDOM III-35
A.Market Analysis III-35
Current and Future Analysis III-35
UK Government Encourages Genetic Testing III-35
Epistem Plc - A Key Player III-35
B.Market Analytics III-36
Table 38: The UK Recent Past, Current and Future Analysis for
Predictive Diagnostics Market Analyzed with Annual Revenue
Figures in US$ Thousand for the Years 2014 through 2020
(includes corresponding Graph/Chart) III-36

Table 39: The UK Historic Review for Predictive Diagnostics
Market Analyzed with Annual Revenue Figures in US$ Thousand
for the Years 2009 through 2013 (includes corresponding
Graph/Chart) III-37

4e. REST OF EUROPE III-38
A.Market Analysis III-38
Strategic Corporate Developments III-38
Select Key Players III-38
B.Market Analytics III-41
Table 40: Rest of European Recent Past, Current and Future
Analysis for Predictive Diagnostics Market Analyzed with
Annual Revenue Figures in US$ Thousand for the Years 2014
through 2020 (includes corresponding Graph/Chart) III-41

Table 41: Rest of European Historic Review for Predictive
Diagnostics Market Analyzed with Annual Revenue Figures in
US$ Thousand for the Years 2009 through 2013 (includes
corresponding Graph/Chart) III-42

5. ASIA-PACIFIC III-43
A.Market Analysis III-43
Table 42: Population Statistics in Asia (Including Japan) and
Percentage of Population Aged Above 65 Years (includes
corresponding Graph/Chart) III-43
B.Market Analytics III-44
Table 43: Asia-Pacific Recent Past, Current and Future
Analysis for Predictive Diagnostics Market Analyzed with
Annual Revenue Figures in US$ Thousand for the Years 2014
through 2020 (includes corresponding Graph/Chart) III-44

Table 44: Asia-Pacific Historic Review for Predictive
Diagnostics Market Analyzed with Annual Revenue Figures in
US$ Thousand for the Years 2009 through 2013 (includes
corresponding Graph/Chart) III-45

6. REST OF WORLD III-46
A.Market Analysis III-46
Product Introductions III-46
Strategic Corporate Developments III-46
Emsurg Healthcare (India) Pvt. Limited - A Key Player III-46
B.Market Analytics III-47
Table 45: Rest of World Recent Past, Current and Future
Analysis for Predictive Diagnostics Market Analyzed with
Annual Revenue Figures in US$ Thousand for the Years 2014
through 2020 (includes corresponding Graph/Chart) III-47

Table 46: Rest of World Historic Review for Predictive
Diagnostics Market Analyzed with Annual Revenue Figures in
US$ Thousand for the Years 2009 through 2013 (includes
corresponding Graph/Chart) III-48


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 49 (including Divisions/Subsidiaries - 51)

The United States (24)
Canada (1)
Europe (17)
- Germany (4)
- The United Kingdom (5)
- Spain (1)
- Rest of Europe (7)
Asia-Pacific (Excluding Japan) (7)
Middle East (2)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Future Horizons and Growth Strategies in the Global Clinical Chemistry and Immunodiagnostics Market 2015: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the Global Clinical Chemistry and Immunodiagnostics Market 2015: Supplier Shares and Country Forecasts

  • $ 23 500
  • Industry report
  • June 2015
  • by Venture Planning Group

Complete report $37,500.  DataPack (test volumes, sales forecasts, supplier shares) $23,500. “Future Horizons and Growth Strategies in the Global Clinical Chemistry and Immunodiagnostics Market 2015” ...

2015 New Frontiers in Clinical Chemistry and Immunodiagnostics: Global Challenges, Emerging Technologies, Competitive Landscape

2015 New Frontiers in Clinical Chemistry and Immunodiagnostics: Global Challenges, Emerging Technologies, Competitive Landscape

  • $ 23 500
  • Industry report
  • June 2015
  • by Venture Planning Group

Complete report $37,500.  DataPack (test volumes, sales forecasts, supplier shares) $23,500. “2015 New Frontiers in Clinical Chemistry and Immunodiagnostics: Global Challenges, Emerging Technologies, ...

2015-2019 World Clinical Chemistry and Immunodiagnostic Markets: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Japan, Spain, UK, US

2015-2019 World Clinical Chemistry and Immunodiagnostic Markets: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Japan, Spain, UK, US

  • $ 23 500
  • Industry report
  • June 2015
  • by Venture Planning Group

Complete report $37,500.  DataPack (test volumes, sales forecasts, supplier shares) $23,500. “2015-2019 World Clinical Chemistry and Immunodiagnostic Markets” is VPGMarketResearch.com new seven-c ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.